EXHIBIT 10.11 RESEARCH AND DEVELOPMENT AGREEMENT This Research and Development Agreement (this "AGREEMENT"), effective as of January 4, 2006 (the "EFFECTIVE DATE"), is entered into by and between SAFETEK INTERNATIONAL, INC., a corporation organized...Research and Development Agreement • January 5th, 2006 • Safetek International Inc • Miscellaneous plastics products
Co-Optimization of Fuels & Engines (Co-Optima) MODULAR CRADA STEVENSON-WYDLER (15 U.S.C. 3710a) COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (hereinafter “CRADA”) betweenResearch and Development Agreement • July 23rd, 2020
1PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCHResearch and Development Agreement • November 13th, 2018 • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • March 15th, 2018
BACKGROUNDResearch and Development Agreement • May 14th, 1998 • Allergan Specialty Therapeutics Inc • Pharmaceutical preparations • California
RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • November 27th, 2002 • Constar International Inc • Miscellaneous plastics products • Pennsylvania
This RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of November 20, 2002 between CarnaudMetalbox plc, a public limited company formed under the laws of England and Wales (“Carnaud”), Crown Cork & Seal Technologies Corporation (“Crown Technologies” and, collectively with Carnaud, the “Crown Entities”) and Constar, Inc., a Delaware corporation (“Constar, Inc.”).
BACKGROUNDResearch and Development Agreement • October 4th, 2000 • Introgen Therapeutics Inc • Pharmaceutical preparations • Texas
Cooperative Research and Development AgreementResearch and Development Agreement • April 13th, 2021
May 7, 2007 Dr. Charles Link NewLink Genetics Corporation Suite 3900 Ames, IA 50010 USAResearch and Development Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • District of Columbia
Re: Letter of Intent for a Cooperative Research and Development Agreement #02166 NCI Principal Investigators: Drs. Sherry S. Ansher, Lee Jia and Howard Streicher Collaborator Investigators: Drs. Charles Link and Nicholas Vahanian
EX-10.26 2 d270314dex1026.htm RESEARCH AND DEVELOPMENT AGREEMENT ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN...Research and Development Agreement • May 5th, 2020 • Delaware
This Research and Development Agreement (the “Agreement”), effective as of November 1, 2011 (the “Effective Date”), is by and between Dexcom, Inc., a Delaware Corporation having its principal place of business at 6340 Sequence Drive, San Diego, California 92121 (“Dexcom”), and Roche Diagnostics Operations, Inc., a Delaware corporation having its principal place of business at 9115 Hague Road, Indianapolis, Indiana 46250 (“Roche”). Roche and Dexcom are each referred to herein as a “Party” and collectively as the “Parties”.
NON-STANDARD NAVY COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT BETWEEN [full name of NAVY COLLABORATOR then acronym] AND [full name of NON-NAVY COLLABORATOR then acronym]Research and Development Agreement • September 28th, 2018
Research and Development AgreementResearch and Development Agreement • June 30th, 2020
EXHIBIT 10.8 RESEARCH AND DEVELOPMENT AGREEMENT This Research and Development Agreement ("Agreement"), effective as of March 10, 2000 ("Effective Date"), is between CytoGenix, Inc., a Nevada corporation ("CytoGenix"), and Argyll Scientific, L.L.C., a...Research and Development Agreement • September 25th, 2001 • Cytogenix Inc • Services-medical laboratories • Texas
AMENDMENT NO. 2Research and Development Agreement • May 6th, 2019 • Delaware
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ].
BASIC SCIENCE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA)Research and Development Agreement • September 15th, 2020 • District of Columbia
NAVY COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT BETWEENResearch and Development Agreement • October 23rd, 2014
SHORT-FORM COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • May 5th, 2020
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCHResearch and Development Agreement • December 29th, 2014 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
Cooperative Research and Development Agreement (CRADA) HandbookResearch and Development Agreement • January 14th, 2008
The National Geospatial-Intelligence Agency (NGA) is a Department of Defense (DoD) combat support agency and a member of the national Intelligence Community (IC). NGA develops imagery and map-based intelligence solutions for U.S. national defense, homeland security and safety of navigation. Formed in 1996 as the National Imagery and Mapping Agency (NIMA) its goal was to centralize responsibility for imagery and mapping. In late 2003, NIMA was renamed the National Geospatial-Intelligence Agency (NGA) to better reflect its main mission of geospatial intelligence (GEOINT) analysis.
Research and Development AgreementResearch and Development Agreement • March 7th, 2007 • Topspin Medical Inc • Electromedical & electrotherapeutic apparatus
This Research and Development Agreement (this “Agreement”), effective as of September 13, 2006 (the “Effective Date”), is entered into by and between TopSpin Medical Inc. a Delaware corporation (“TopSpin”) for itself and/or at TopSpin’s election, TopSpin Medical (Israel) Ltd., a wholly owned subsidiary of TopSpin, an Israeli corporation of 2 Yodfat St. Global Park, Lod (“TopSpin Israel”) and/or TopSpin Urology Ltd. a wholly owned subsidiary of TopSpin, an Israeli corporation of 2 Yodfat St. Global Park, Lod (“TopSpin Urology”) (TopSpin and/or TopSpin Israel and/or TopSpin Urology shall be referred to herein as the “Company”), Technion Research & Development Foundation Ltd., an Israeli corporation of the Technion City, Haifa 32000 (“TRDF”) and Dr. Aharon Blank I.D. No.029099330 of Naaman 24, Kefar Veradim (“Investigator”).
RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • July 2nd, 2004 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations • Texas
THIS RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is made as of the 20th day of June, 2003, by and between FORMULATION TECHNOLOGIES L.L.C., d/b/a PharmaForm, with an office located at 1006 Yeager Lane, Bldg. D, Suite 101, Austin TX 78753 (“PharmaForm”), and AUXILIUM PHARMACEUTICALS, INC. with an office located at 160 W. Germantown Pike, Norristown, PA 19401 (“AUXILIUM”).
Research and Development Agreement (Pre-Commercial Procurement)Research and Development Agreement • January 20th, 2023
RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • June 27th, 2014 • BioRestorative Therapies, Inc. • Services-misc health & allied services, nec • New York
THIS RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”), dated as of March 19, 2014 (the “Effective Date”), is made and entered into by and between BioRestorative Therapies, Inc., a Nevada corporation (“BRT”), and Rohto Pharmaceutical Co., Ltd., a Japanese corporation (“Rohto”) (collectively the “Parties” or individually a “Party”).
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCHResearch and Development Agreement • May 19th, 2014 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
PRINCIPAL INVESTIGATOR INITIATED STUDY COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA)Research and Development Agreement • September 22nd, 2020 • District of Columbia
ContractResearch and Development Agreement • May 5th, 2020 • Pennsylvania
EX-10.8 10 dex108.htm FORM OF RESEARCH AND DEVELOPMENT AGREEMENT Confidential Treatment has been requested by Constar International Inc. pursuant to Rule 406. All non-public information has been filed with the Securities and Exchange Commission. EXHIBIT 10.8 RESEARCH AND DEVELOPMENT AGREEMENT This RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of , 2002 between CarnaudMetalbox plc, a public limited company formed under the laws of England and Wales (“Carnaud”), Crown Cork & Seal Technologies Corporation (“Crown Technologies” and, collectively with Carnaud, the “Crown Entities”) and Constar, Inc., a Delaware corporation (“Constar, Inc.”). BACKGROUND A. The Crown Entities currently provide certain research and development services to Constar, Inc. B. Crown Cork & Seal Company, Inc. (“Crown”) and Constar International Inc. (“Constar”) are contemplating that an initial public offering will be made of all of the capital stock of Constar (the “Initial Public Offerin
RECITALSResearch and Development Agreement • April 10th, 1998 • Clinichem Development Inc • Pharmaceutical preparations • Quebec
This Research and Development Agreement (the "Agreement") is made as of the thirtieth day of June, 1999 by and between Sabratek Corporation, a Delaware corporation ("SBTK"), and Systle Corporation, a Delaware corporation ("Systle"). RECITALS A. SBTK...Research and Development Agreement • July 16th, 1999 • Sabratek Corp • Electromedical & electrotherapeutic apparatus • Illinois
NAVY COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT BETWEENResearch and Development Agreement • September 10th, 2014
JOINT RESEARCH AND DEVELOPMENT AGREEMENT BETWEEN UNIVERSITI SAINS MALAYSIA AND ABC SDN BHD IN RELATION TO DEVELOPMENT OF ……………..Research and Development Agreement • January 21st, 2021
RESEARCH AND DEVELOPMENT AGREEMENT THIS RESEARCH AND DEVELOPMENT AGREEMENT is made on the ___________ day of _____________ 20 (hereinafter referred to as “Agreement”);
AMENDMENT #2 TO THE RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • March 5th, 2019 • Ziopharm Oncology Inc • Pharmaceutical preparations
This AMENDMENT #2 (“AMENDMENT #2”) to the RESEARCH AND DEVELOPMENT AGREEMENT (the “AGREEMENT”) is entered into as of January 17, 2017 by and among THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“UTMDACC”), INTREXON CORPORATION (“INTREXON”) and ZIOPHARM ONCOLOGY, INC. (“ZIOPHARM”). Capitalized terms used herein and not defined shall have the meaning ascribed to them in the AGREEMENT.
Medicine Research and Development AgreementResearch and Development Agreement • October 7th, 2009 • Lid Hair Studios International, Inc. • Services-personal services
Under this Agreement, both Party A and Party B have come to terms in accordance with the relevant regulations of Contracts Law to research and develop and apply for production approval for five new “Pediatric cold-curing medicines”: Xiaoer Kechuanling Granule, Xiaoer Fuxiening Grunules, Xiaoer Digesting Tablet, Xiaoer Kangganjiedu Grannules, and Xiaoer Jianpibuxue Granules.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*****], HAS BEEN OMITTED BECAUSE ZIOPHARM ONCOLOGY, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZIOPHARM ONCOLOGY, INC....Research and Development Agreement • March 2nd, 2020 • Ziopharm Oncology Inc • Pharmaceutical preparations • New York
This Fifth Amendment to Research and Development Agreement (this “Fifth Amendment”) is made as of October 22, 2019 (the “Fifth Amendment Effective Date”), by and among THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a member institution of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), and ZIOPHARM ONCOLOGY, INC., a Delaware corporation (“ZIOPHARM”).
Inbred Popcorn Research and Development AgreementResearch and Development Agreement • July 29th, 2014 • Iowa
This AGREEMENT made this by and between the Iowa State University Research Foundation, Inc. (hereinafter called ISURF), and (hereinafter called COMPANY).
Confidential Treatment Requested Under 17 C.F.R. (S)(S) 200.80(b)(4) 200.83 and 230.406 RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • February 9th, 2000 • Diversa Corp • Services-commercial physical & biological research • Delaware
